Eli Lilly And Co (NYSE:LLY) has issued a series of cease-and-desist letters to U.S. healthcare providers, including telehealth companies, wellness centers, and medical spas, demanding they halt the promotion of compounded versions of the company’s weight-loss drugs, Mounjaro and Zepbound that contain tirzepatide. Through its legal representation, the U.S. pharmaceutical giant argues that these compounded drugs are no longer necessary as the supply of its brand-name medications has improved. The FDA allows compounding pharmacies to produce copycat versions of brand-name drugs during shortages. Also Read: Eli Lilly’s Legal Battle Against Fake Compounded Tirzepatide Products: Bacteria, Impurities Detected. While ...